Effects Of Ginkgolide On Th1 And Th17 Cells Of CD4~+T Lymphocyte Subsets In Peripheral Blood Of Patients With Acute Cerebral Infarction

Objective To investigate the effect of GDLMI on Th1 and Th17 cells of CD4~+T lymphocyte subsets in peripheral blood of patients with ACI and its effect on the recovery of neurological function.Methods 80 patients with ACI in the Department of Neurology,the first Hospital of Lanzhou University were stochastically divided into matched group and observed group.According to the Chinese guidelines for diagnosis and treatment of Acute Ischemic Stroke(2018),two groups of patients were given standard therapy,and the observed group was treated with GDLMI(containing ginkgolide 25mg)on the basis of standard therapy.14 days of therapy was a course.The changes of neurological function of the two groups were evaluated by NIHSS score before therapy,7 days and14 days after therapy,and the prognosis was evaluated by m RS 30 days after therapy.At the same time,30 patients in each group were randomly selected before therapy and 7 days after therapy,and the levels of Th1 and Th17 cells of CD4~+T lymphocyte subsets were detected by flow cytometry and Flowjo10 software.Results1.Evaluation of the curative effect of two groups of patients:before therapy,there was no observably difference in NIHSS score between the matched group and the observed group,but after 7 days and 14 days of therapy,the NIHSS scores of the two groups were observably lower than before(P<0.05).The decrease in the observed group was more obvious than that the matched group after therapy,and the difference was statistically significant(P<0.05),and there was observably difference in the overall effective rate between the two groups(P<0.05).2.Comparison of prognosis between the two groups:during the follow-up for 30days,there were 19 patients with good prognosis in the matched group and 23 patients in the observed group.There was no observably difference between the two groups(P>0.05).3.Changes of serum hs-CRP levels in two groups:before therapy,there was no striking differences in the level of hs-CRP between two groups,but after 7 days of therapy,the level of hs-CRP in the two groups decreased,and the difference was statistically significant(P<0.05),and there was no striking difference between the two groups(P>0.05).4.Changes of T cell subsets in peripheral blood of patients in two groups:before therapy,there was no striking difference in the level of CD4~+T lymphocytes,Th1 and Th17 cells between the two groups.After 7 days of therapy,there was no striking difference in the level of CD4~+T lymphocytes between the two groups,and there was no striking difference between the two groups.The level of Th1 cells in the two groups was observably lower than that before therapy,and there was significant difference between the two groups(P<0.05).After 7 days of therapy,the level of Th17 cells decreased only in the observed group(P<0.05).5.Relationship between hs-CRP and Th17 cells:There was a positive correlation between the level of hs-CRP and Th17 cells before therapy.Conclusion1.Ginkgo diterpene lactones can reduce the levels of Th1 and Th17 cells in peripheral blood of patients with ACI.2.Ginkgo diterpene lactones can improve neurological impairment in patients.